ArticleJournal of cardiovascular pharmacology2025
Gene- and cell-based therapy in cardiovascular diseases.
Article in Journal of cardiovascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is one of the leading causes of mortality in humans, with a high prevalence. Moreover, this disease poses a serious threat to the economy. At present, treatment strategies are inadequate in both the prevention and cure of CVD. Thus, further investigations are required for the development of novel therapeutic options. Notably, gene- and cell-based therapies exhibit potential in the treatment of CVD. In the present article, gene- and cell-based therapies were reviewed in the context of CVD. The present review may provide a novel theoretical basis for improving the efficacy of CVD treatment, and demonstrate the potential of gene- and cell-based therapy in clinical practice. In addition, market analysis was carried out in the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.